DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects
| Status: | Completed |
|---|---|
| Conditions: | HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/9/2018 |
| Start Date: | January 2012 |
| End Date: | April 2015 |
DRIVESHAFT : Darunavir/Ritonavir In Virologically-suppressed Experienced Subjects Halving an Antiretroviral by Finetuning Therapy - A Phase IV Randomized, Open-Label Study to Evaluate in HIV-1 Infected , Virologically-suppressed Patients on Regimens With Darunavir 600mg/ Ritonavir 100mg Twice-daily Switching to Darunavir 800mg/ Ritonavir 100mg Once-daily Versus Continuing Darunavir 600mg/ Ritonavir 100mg Twice-daily Containing Regimens
Darunavir is a nonpeptidic protease inhibitor with a high genetic barrier to resistance that
evolved from a prototype compound synthesized using structure-based design strategies.
Once-daily darunavir at 800mg boosted with 100mg of ritonavir is an effective antiretroviral
agent indicated for HIV-infected treatment-naïve patients. In treatment-experienced patients,
darunavir was initially approved for twice-daily administration boosted with twice-daily
ritonavir at 600mg and 100mg, respectively. Recently, once-daily darunavir/ritonavir was
approved for use in treatment-experienced adult patients with viremia with no darunavir
resistance mutations. In treatment-experienced patients with viral suppression, switching
from an antiretroviral taken twice-daily to a once-daily dose is an attractive option to
promote greater patient acceptability and adherence, and potentially minimize side effects
and toxicities. Because of darunavir/ritonavir's high genetic barrier to resistance and
well-established safety profile at a once-daily dose, switching patients with virologic
suppression from twice-daily darunavir/ritonavir to once-daily darunavir/ritonavir will
likely confer attributes more favorable to patients through a simplified dosing schedule and
lower potential for lipid elevation without the loss of virologic control. DRIVESHAFT is a
48-week Phase 4, randomized, open label, comparative study. The study will be conducted in 60
HIV-1 infected, antiretroviral experienced, virologically-suppressed patients on regimens
containing darunavir 600mg/ ritonavir 100mg twice-daily and a minimum of two other
antiretrovirals, with a history of 0-1 darunavir-associated resistance mutations. Subjects
will be randomized 1:1 to switch to darunavir 800mg/ ritonavir 100mg once-daily or continue
on their current regimen. Rates of virologic suppression of once-daily darunavir/ritonavir
regimens relative to darunavir/ritonavir twice-daily regimens will be compared, and safety,
change from baseline fasting lipid parameters, and adherence will be evaluated.
evolved from a prototype compound synthesized using structure-based design strategies.
Once-daily darunavir at 800mg boosted with 100mg of ritonavir is an effective antiretroviral
agent indicated for HIV-infected treatment-naïve patients. In treatment-experienced patients,
darunavir was initially approved for twice-daily administration boosted with twice-daily
ritonavir at 600mg and 100mg, respectively. Recently, once-daily darunavir/ritonavir was
approved for use in treatment-experienced adult patients with viremia with no darunavir
resistance mutations. In treatment-experienced patients with viral suppression, switching
from an antiretroviral taken twice-daily to a once-daily dose is an attractive option to
promote greater patient acceptability and adherence, and potentially minimize side effects
and toxicities. Because of darunavir/ritonavir's high genetic barrier to resistance and
well-established safety profile at a once-daily dose, switching patients with virologic
suppression from twice-daily darunavir/ritonavir to once-daily darunavir/ritonavir will
likely confer attributes more favorable to patients through a simplified dosing schedule and
lower potential for lipid elevation without the loss of virologic control. DRIVESHAFT is a
48-week Phase 4, randomized, open label, comparative study. The study will be conducted in 60
HIV-1 infected, antiretroviral experienced, virologically-suppressed patients on regimens
containing darunavir 600mg/ ritonavir 100mg twice-daily and a minimum of two other
antiretrovirals, with a history of 0-1 darunavir-associated resistance mutations. Subjects
will be randomized 1:1 to switch to darunavir 800mg/ ritonavir 100mg once-daily or continue
on their current regimen. Rates of virologic suppression of once-daily darunavir/ritonavir
regimens relative to darunavir/ritonavir twice-daily regimens will be compared, and safety,
change from baseline fasting lipid parameters, and adherence will be evaluated.
Inclusion Criteria:
1. ART-experienced, HIV-1 infected subjects ≥18 years of age.
2. A female subject is eligible to enter and participate in the study if she:
1. is of non-childbearing potential defined as either post-menopausal (12 months of
spontaneous amenorrhea and ≥45 years of age) or physically incapable of becoming
pregnant with documented tubal ligation, hysterectomy, or bilateral oophorectomy
or,
2. is of child-bearing potential, with a negative pregnancy test at both Screen and
Day 1 and agrees to one of the following methods of contraception to avoid
pregnancy:
- Complete abstinence from intercourse from 2 weeks prior to administration of
study medications, throughout the study, and for at least 2 weeks after
discontinuation of all study medications.
- Double barrier method (male condom/spermicide, male condom/diaphragm,
diaphragm/spermicide).
- Approved hormonal contraception may be administered with darunavir/ritonavir
- Any intrauterine device (IUD) with published data showing that the expected
failure rate is <1% per year
- Any other method with published data showing that the expected failure rate
is <1% per year.
Any contraception method must be used consistently and in accordance with the approved
product label. All subjects participating in the study should be counseled on safer
sexual practices including the use of effective barrier methods (e.g. male
condom/spermicide).
3. CD4 >50 cells/mm3
4. HIV-1 RNA concentrations at undetectable levels (according to local assay being used)
for at least 12 weeks on stable current regimen
5. Current regimen includes darunavir/ritonavir 600/100 mg twice-daily plus a minimum of
two other antiretrovirals
6. Negative serum pregnancy test at screening visit
Exclusion Criteria:
Subjects meeting any of the following criteria must not be enrolled in the study:
1. Known hypersensitivity reaction to agents being utilized in the study
2. >1 cumulative darunavir associated mutations (V11I, V32I, L33F, I47V, I50V, I54L or M,
T74P, L76V, I84V, or L89V) detected from any previous genotype or a VircoTYPE HIV-1
darunavir fold-change >10.0 on any previous virtual phenotype
3. Pregnant or breast feeding woman
4. Liver dysfunction with Child-Pugh class C disease or decompensated cirrhosis
We found this trial at
1
site
Click here to add this to my saved trials
